Silverarc Capital Management
Latest statistics and disclosures from Silverarc Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ABVX, COGT, URGN, KALV, CELC, and represent 30.35% of Silverarc Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CELC (+$29M), IMNM (+$24M), Uniqure Nv call (+$17M), KALV (+$17M), COGT (+$15M), PFE (+$10M), GH (+$9.4M), PRAX (+$9.2M), CNTA (+$7.9M), SYRE (+$6.2M).
- Started 21 new stock positions in EWTX, KYMR, RLAY, XFOR, FULC, SRZN, PALI, NXTC, SLNO, Kalvista Pharmaceuticals. GH, IBIO, TARS, FDMT, Uniqure Nv call, ADGM, CTMX, Fulcrum Therapeutics, SYRE, IMNM, PFE.
- Reduced shares in these 10 stocks: RNA (-$37M), AKRO (-$31M), , RYTM (-$25M), INSM (-$24M), CDTX (-$21M), OLMA (-$18M), ABVX (-$16M), CYTK (-$12M), CGON (-$12M).
- Sold out of its positions in Atyr Pharma Inc put, AKRO, ARCT, Arcturus Therapeutics Hldg I put, RNA, BCAX, BDSX, BBOT, CAMP, Capricor Therapeutics.
- Silverarc Capital Management was a net seller of stock by $-152M.
- Silverarc Capital Management has $720M in assets under management (AUM), dropping by -2.91%.
- Central Index Key (CIK): 0001816307
Tip: Access up to 7 years of quarterly data
Positions held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 68 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Abivax Sa Sponsored Ads (ABVX) | 7.9 | $57M | -21% | 422k | 134.85 |
|
| Cogent Biosciences (COGT) | 6.1 | $44M | +52% | 1.2M | 35.52 |
|
| Urogen Pharma (URGN) | 5.7 | $41M | +10% | 1.7M | 23.42 |
|
| Kalvista Pharmaceuticals (KALV) | 5.4 | $39M | +78% | 2.4M | 16.15 |
|
| Celcuity (CELC) | 5.2 | $37M | +322% | 375k | 99.74 |
|
| Nuvalent Inc-a (NUVL) | 4.4 | $31M | -16% | 311k | 100.59 |
|
| Dianthus Therapeutics (DNTH) | 4.3 | $31M | +11% | 750k | 41.21 |
|
| Kodiak Sciences (KOD) | 4.0 | $29M | +2% | 1.0M | 27.96 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.4 | $24M | +61% | 83k | 294.74 |
|
| Immunome (IMNM) | 3.4 | $24M | NEW | 1.1M | 21.48 |
|
| Fractyl Health (GUTS) | 3.0 | $22M | -7% | 9.8M | 2.20 |
|
| Uniqure Nv Call Call Option | 2.4 | $17M | NEW | 721k | 23.93 |
|
| Monte Rosa Therapeutics (GLUE) | 2.2 | $16M | +48% | 1.0M | 15.68 |
|
| Veracyte (VCYT) | 2.1 | $15M | +51% | 358k | 42.10 |
|
| Cg Oncology (CGON) | 2.1 | $15M | -43% | 361k | 41.52 |
|
| Rhythm Pharmaceuticals (RYTM) | 2.0 | $15M | -63% | 136k | 107.04 |
|
| Syndax Pharmaceuticals (SNDX) | 1.9 | $14M | +38% | 643k | 21.01 |
|
| Biogen Idec (BIIB) | 1.8 | $13M | -6% | 75k | 175.99 |
|
| Insmed Com Par $.01 (INSM) | 1.7 | $12M | -65% | 71k | 174.04 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.6 | $12M | +224% | 458k | 25.01 |
|
| Miragen Therapeutics (VRDN) | 1.5 | $11M | +34% | 349k | 31.12 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.5 | $11M | -8% | 49k | 213.24 |
|
| Pfizer (PFE) | 1.4 | $10M | NEW | 419k | 24.90 |
|
| Benitec Biopharma Com New (BNTC) | 1.4 | $9.9M | +164% | 732k | 13.47 |
|
| Avalo Therapeutics Com New (AVTX) | 1.3 | $9.5M | -27% | 524k | 18.16 |
|
| Guardant Health (GH) | 1.3 | $9.4M | NEW | 92k | 102.14 |
|
| Oric Pharmaceuticals (ORIC) | 1.3 | $9.1M | -42% | 1.1M | 8.18 |
|
| Vaxcyte (PCVX) | 1.0 | $6.9M | -52% | 149k | 46.14 |
|
| Trevi Therapeutics (TRVI) | 0.9 | $6.8M | -8% | 541k | 12.52 |
|
| Gossamer Bio (GOSS) | 0.9 | $6.6M | -55% | 2.1M | 3.10 |
|
| Spyre Therapeutics Com New (SYRE) | 0.9 | $6.2M | NEW | 188k | 32.76 |
|
| Lexeo Therapeutics (LXEO) | 0.9 | $6.1M | -20% | 618k | 9.93 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.8 | $6.1M | -27% | 506k | 12.08 |
|
| Cerus Corporation (CERS) | 0.8 | $5.8M | +3% | 2.8M | 2.06 |
|
| Compass Therapeutics (CMPX) | 0.8 | $5.6M | -62% | 1.1M | 5.37 |
|
| Soleno Therapeutics (SLNO) | 0.8 | $5.4M | NEW | 118k | 46.30 |
|
| Compugen Ord (CGEN) | 0.7 | $5.3M | +5% | 3.5M | 1.53 |
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $5.2M | -45% | 191k | 27.16 |
|
| Olema Pharmaceuticals (OLMA) | 0.7 | $5.2M | -77% | 206k | 25.00 |
|
| Erasca (ERAS) | 0.7 | $4.9M | -3% | 1.3M | 3.72 |
|
| Kalvista Pharmaceuticals Call Call Option | 0.7 | $4.7M | NEW | 291k | 16.15 |
|
| Fulcrum Therapeutics (FULC) | 0.6 | $4.5M | NEW | 395k | 11.31 |
|
| Fulcrum Therapeutics Call Call Option | 0.6 | $4.4M | NEW | 392k | 11.31 |
|
| Aardvark Therapeutics (AARD) | 0.6 | $4.0M | 304k | 13.12 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $3.8M | +5% | 2.0M | 1.91 |
|
| Surrozen Com New (SRZN) | 0.5 | $3.6M | NEW | 157k | 22.60 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.5 | $3.5M | +85% | 308k | 11.43 |
|
| Mineralys Therapeutics (MLYS) | 0.5 | $3.4M | +18% | 95k | 36.29 |
|
| Relay Therapeutics (RLAY) | 0.5 | $3.4M | NEW | 398k | 8.46 |
|
| Abeona Therapeutics Com New (ABEO) | 0.5 | $3.3M | -36% | 628k | 5.27 |
|
| Tela Bio (TELA) | 0.4 | $3.1M | -4% | 2.6M | 1.18 |
|
| Uniqure Nv SHS (QURE) | 0.4 | $3.0M | -72% | 126k | 23.93 |
|
| Tarsus Pharmaceuticals (TARS) | 0.4 | $3.0M | NEW | 36k | 81.88 |
|
| Kymera Therapeutics (KYMR) | 0.4 | $2.7M | NEW | 35k | 77.81 |
|
| Ultragenyx Pharmaceutical In Call Call Option | 0.4 | $2.5M | -79% | 110k | 23.00 |
|
| Nextcure Com New (NXTC) | 0.3 | $2.5M | NEW | 176k | 14.19 |
|
| Elutia Cl A Com (ELUT) | 0.3 | $1.9M | -3% | 2.8M | 0.69 |
|
| Sionna Therapeutics (SION) | 0.2 | $1.7M | -61% | 42k | 41.14 |
|
| Cytomx Therapeutics (CTMX) | 0.2 | $1.6M | NEW | 386k | 4.26 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.2 | $1.4M | NEW | 357k | 4.00 |
|
| Edgewise Therapeutics (EWTX) | 0.1 | $1.0M | NEW | 42k | 24.82 |
|
| Radiopharm Theranostics Sponsored Ads (RADX) | 0.1 | $978k | 187k | 5.22 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.1 | $750k | NEW | 100k | 7.50 |
|
| Adagio Med Hldgs (ADGM) | 0.1 | $536k | NEW | 515k | 1.04 |
|
| Rapport Therapeutics (RAPP) | 0.0 | $293k | -95% | 9.7k | 30.34 |
|
| Palisade Bio (PALI) | 0.0 | $240k | NEW | 102k | 2.35 |
|
| Ibio Com New (IBIO) | 0.0 | $205k | NEW | 106k | 1.93 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $2.5k | 105k | 0.02 |
|
Past Filings by Silverarc Capital Management
SEC 13F filings are viewable for Silverarc Capital Management going back to 2020
- Silverarc Capital Management 2025 Q4 filed Feb. 12, 2026
- Silverarc Capital Management 2025 Q3 filed Nov. 12, 2025
- Silverarc Capital Management 2025 Q2 filed Aug. 14, 2025
- Silverarc Capital Management 2025 Q1 filed May 14, 2025
- Silverarc Capital Management 2024 Q4 filed Feb. 14, 2025
- Silverarc Capital Management 2024 Q3 filed Nov. 14, 2024
- Silverarc Capital Management 2024 Q2 filed Aug. 14, 2024
- Silverarc Capital Management 2024 Q1 filed May 15, 2024
- Silverarc Capital Management 2023 Q4 filed Feb. 14, 2024
- Silverarc Capital Management 2023 Q3 filed Nov. 13, 2023
- Silverarc Capital Management 2023 Q2 filed Aug. 14, 2023
- Silverarc Capital Management 2023 Q1 filed May 15, 2023
- Silverarc Capital Management 2022 Q4 filed Feb. 14, 2023
- Silverarc Capital Management 2022 Q3 filed Oct. 28, 2022
- Silverarc Capital Management 2022 Q2 filed July 25, 2022
- Silverarc Capital Management 2022 Q1 filed May 13, 2022